ArticleBritish journal of cancer2014
Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer.
Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 5 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Clinicopathological and prognostic value of epithelial cell adhesion molecule in solid tumours: a meta-analysis.Frontiers in oncology · 2023Pooled it
- Is Ep-CAM Expression a Diagnostic and Prognostic Biomarker for Colorectal Cancer? A Systematic Meta-Analysis.EBioMedicine · 2017Pooled it
- Copy number alterations and allelic ratio in relation to recurrence of rectal cancer.BMC genomics · 2015Pooled it
- Survivin and angiotensin-converting enzyme polymorphisms with risk of colorectal cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2015Pooled it
- Prognostic Value of Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.PloS one · 2015Pooled it
- Cancer Stem Cells in Colorectal Cancer: From Molecular Mechanisms to Diagnosis, Prognosis and Therapy Implications.Cancers · 2026Review
- DSSMST: A Deterministic State Space Model for Self-Supervised Spatial Domain Identification in Spatial Transcriptomics.Biochemical genetics · 2026Article
- Article
- Predictive value of a mesenchymal phenotype grading system combining tumor budding and FRMD6 expression for disease-free survival in colorectal carcinomas.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Article
- Exosomes: a potential tool in the diagnosis, prognosis and treatment of patients with colorectal cancer.Future oncology (London, England) · 2025Review
- Three-Dimensional Magnetic Bioprinting Spheroids as an In Vitro Model to Study the Oviductal Physiology.Molecular reproduction and development · 2025Article
- Article
- Evaluation and Clinicopathological Correlation of ALDH1 in Colorectal Adenoma with Low-/High-Grade Dysplasia and Carcinoma.South Asian journal of cancer · 2024Article
- Review
- Unraveling the multifaceted role of EpCAM in colorectal cancer: an integrated review of its function and interplay with non-coding RNAs.Medical oncology (Northwood, London, England) · 2023Review
- Immuno-Contexture and Immune Checkpoint Molecule Expression in Mismatch Repair Proficient Colorectal Carcinoma.Cancers · 2023Article
- Cloning, Expression, and Purification of the Human Synthetic Survivin Protein in Escherichia coli Using Response Surface Methodology (RSM).Molecular biotechnology · 2023Article
- Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- The association between Annexin A2 and epithelial cell adhesion molecule in breast cancer cells.Cancer reports (Hoboken, N.J.) · 2022Article
- Tumor-suppressive role of Smad ubiquitination regulatory factor 2 in patients with colorectal cancer.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumour aggressiveness might be related to the degree of main cancer hallmark acquirement of tumour cells, reflected by expression levels of specific biomarkers. We investigated the expression of Aldh1, Survivin, and EpCAM, together reflecting main cancer hallmarks, in relation to clinical outcome of colorectal cancer (CRC) patients.
methodsImmunohistochemistry was performed using a tumour tissue microarray of TNM (Tumour, Node, Metastasis)-stage I-IV CRC tissues. Single-marker expression or their combination was assessed for associations with the clinical outcome of CRC patients (N=309).
resultsIncreased expression of Aldh1 or Survivin, or decreased expression of EpCAM was each associated with poor clinical outcome, and was therefore identified as clinically unfavourable expression. Analyses of the combination of all three markers showed worse clinical outcome, specifically in colon cancer patients, with an increasing number of markers showing unfavourable expression. Hazard ratios ranged up to 8.3 for overall survival (P<0.001), 36.6 for disease-specific survival (P<0.001), and 27.1 for distant recurrence-free survival (P<0.001).
conclusionsOur data identified combined expression levels of Aldh1, Survivin, and EpCAM as strong independent prognostic factors, with high hazard ratios, for survival and tumour recurrence in colon cancer patients, and therefore reflect tumour aggressiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.